(A) NIH ordinal scale for COVID-19 clinical severity. (B) Frequencies of major immune subsets. Significance determined by unpaired Wilcoxon test with BH correction: *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. (C) Heatmap of indicated immune parameters by row; donor type, disease severity, and mortality indicated across top. (D) UMAP projection of aggregated flow cytometry data. (E) Transformed UMAP projection; density contours drawn separately for healthy donor (HD), recovered donor (RD), and COVID-19 subjects (see Methods). (F) Bars represent mean of UMAP Component 1. Dots represent individual subjects; bars shaded by subject group and/or severity score. (G) Density contour plots indicating variation of specified immune features across UMAP Component coordinates. Relative expression (according to heat scale) shown for both individual patients (points) and overall density (contours). Spearman’s Rank Correlation coefficient (ρ) and p-value for each feature vs. Component 1 (C1) and Component 2 (C2) shown. (H) (Left) Spearman correlation between UMAP Components 1 and 2 and FlowSOM clusters. (Right) Select FlowSOM clusters and their protein expression. (I) Spearman correlation between UMAP Components 1 and 2 and clinical metadata. (J) Heatmap of immune parameters used to define Immunotype 3 indicated by row; disease severity and mortality indicated across top. (K) (Left) Transformed UMAP projection; patient status for Immunotype 3 indicated by color. (Right) Spearman correlation between Immunotype 3 and disease severity, mortality, and UMAP Components.